biologit

We are excited to be attending the annual DIA Global Pharmacovigilance and Risk Management Strategies Conference (DIA PVRMS), which will be held from Jan. 27 to Jan. 29 in Baltimore. This event will examine the integration of artificial intelligence (AI) and the impact of real-world evidence in safety workflows. Meet with our CEO, Nicole Baker PhD at the conference to discuss how biologit has already transformed the process of literature monitoring using AI and industry-leading data!

At biologit, we are honoured to participate in industry associations such as the International Society of Pharmacovigilance (ISoP Online). In December, our CEO, Nicole Baker PhD had the pleasure of joining other ISOP members at Biogen in Boston for the 8th ISoP Seminar Intelligent Automation in Pharmacovigilance. Thank you to the organisers for a great event. Here, Nicole delivered an insightful presentation entitled “Use cases of Machine Learning (ML) and Natural Language Processing (NLP), while complying with regulatory aspects of AI” outlining the transformative benefits of applying technology solutions to the challenges of literature monitoring. Download our slides to learn more: https://lnkd.in/ehF9k25y #LiteratureScreening #DrugSafety #PatientSafety #Pharmacovigilance #AI #ISoP 

We are delighted to be attending the 37th Pharmacovigilance UK & EU 2025 event with Virtue Insight. Please join us to learn more about the recent trends in #pharmacovigilance. We look forward to seeing you there!

Nicole Baker PhD will be speaking at the Pharmacovigilance UK & EU event in London.

biologit is launching MLM-AI for local literature!!! Are you a Global Pharma/Biotech Company or a Service Provider performing local literature monitoring for Pharmacovigilance? Talk to us!!!

We wish a happy new year to all!!!

From all of us at biologit, wishing all our customers, partners and our extended network a very happy holiday season!

As the year comes to a close, we want to take a moment to reflect and celebrate our achievements, and to express gratitude to our customers, partners, employees and extended network for your continued trust and support.   2024 has been a transformative year for biologit as we focused on advancing our mission to create the industry’s leading literature automation tool, transforming pharmacovigilance worldwide. We are proud to share some of our key accomplishments in 2024.

Unlocking EU Pharmacovigilance for New Drugs! Is your Pharma/Biotech company based outside of Europe and gearing up for a new drug or immunological application in the EU? Look no further! Introducing biologit - Your gateway to EU success! Why choose biologit? ▪ Experienced QPPVs: Our seasoned team of Qualified Persons for Pharmacovigilance (QPPVs) is ready to provide unparalleled support for your regulatory journey. ▪ European Pharmacovigilance Expertise: Navigating the intricacies of the EU Pharmacovigilance is complex; let our experts guide you through the process seamlessly. ▪ Tailored Solutions: We understand the uniqueness of each project; our solutions are crafted to suit your specific needs. Partner with biologit and let's transform your vision into EU reality! 📩 Connect with us to explore possibilities and make your EU submission a resounding success! https://lnkd.in/efXeUTGe

In 2021 the U.S. Food and Drug Administration in conjunction with Health Canada and the MHRA (UK) released guiding principles on Good Machine Learning Practice for Medical Device Development (GMLP). It comprises ten guiding principles published by the FDA, MHRA, and Health Canada, designed to promote safe, effective, and high-quality artificial intelligence systems. Learn how biologit operationalised GMLP iteratively in our AI development process and how we have implemented these principles in the article written by our Senior Platform and AI Engineer Jack Sullivan. https://lnkd.in/ev7G2zs3 #DrugSafety #PatientSafety #Pharmacovigilance #AI #youcandobetterwithourAI #GMLP